BENEVOLENTAI DRUG PIPELINE
UC affects 0.4% of the US population.(1)
20-40% of moderate-severe patients do not respond to anti-TNF therapy, a key treatment approach.(2)
The only oral treatment option currently available has serious side effects.(3)
$8.1bn–$14.9bn annual direct and indirect costs estimated in the US alone.(4)
"Our UC programme demonstrates BenevolentAI's unique ability to uncover novel targets and accelerate the development of de-risked drug candidates by integrating molecular design and precision medicine. The programme unites the best of human and machine intelligence to build confidence in the early discovery phase, with the aim of ultimately providing new therapeutic options for patients.”
(1) Ulcerative Colitis: Epidemiology Forecast to 2029 - GlobalData Report Store, 2021. [Accessed April 2021]
(2) Roda, G et al. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016 Jan; 7(1): e135. doi: 10.1038/ctg.2015.63
(3) U.S. Food & Drug Administration. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). 2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis [Accessed April 2021].
(4) Cohen, R.D et al. Systematic review: The costs of ulcerative colitis in Western countries. Aliment. Pharmacol. Ther. 2010, 31, 693–707.